Work

Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

Year: 2020

Type: review

Abstract: Background: Inflammatory bowel disease (IBD) patients may develop anterior uveitis. Methods: An observational cohort of IBD patients followed new users of (1) tumor necrosis factor inhibitor versus nonbiologic agents or (2) adalimumab versus infliximab until occurrence of anterior uveitis or treatment change/discontinuation. Cox-proportional hazards models estimated hazard ratios in propensity score-matched cohorts of Crohn disease or ulcerative colitis patients. Results: No statistically significant differences in the risk of uveitis were observed between initiators of nonbiologics and tumor necrosis factor inhibitor. Effect estimates for adalimumab versus infliximab were highly imprecise due to limited outcomes. Conclusions: Uveitis risk was not different between IBD patients treated with immunosuppressives.

Source: Crohn s & Colitis 360

DOI: 10.1093/crocol/otaa041

Authors: Julie Barberio, Seoyoung C Kim, Miin Roh, James D Lewis, Rishi J Desai

Institutions: Brigham and Women's Hospital, Harvard University, Joslin Diabetes Center, University of Pennsylvania

Language: English

Topic: Ocular Diseases and Behçet’s Syndrome

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,378